*PLEASE READ!!*

**HELENA LABORATORIES**

**PROCEDURE DOWNLOAD END USER AGREEMENT**

In response to customer requests, Helena is pleased to provide the text for procedural package inserts in a digital format editable for your use. The text for the procedure you requested begins on page three of this document. Helena procedures contain the content outlined in the NCCLS (GP2-A#) format, except in the order sequence required by FDA regulations. As the NCCLS format is a guideline, you may retain these procedures as developed by the manufacturer (adding your title/authorization page) or manipulate the text file to produce your own document, matching the NCCLS section order exactly, if preferred.

We also provide the procedure in an Adobe Acrobat PDF format for download at www.helena.com as a “MASTER” file copy. Below are the specifications and requirements for using these digital files. Following the specifications is the procedure major heading sequence as given in the FDA style. Where there is a difference in order, or other notation in the outline, this will be indicated in braces { }.

WHAT YOU NEED TO KNOW:

1) These files represent the most current revision level to date. Your current product inventory could contain a previous revision level of this procedure.

2) The Microsoft Word document provides the text only from the master procedure, in a single-column format.

* It may not contain any illustrations, graphics or captions that may be part of the master procedure included in the kit.
* The master procedure may have contained special formatting characters, such as subscripts, superscripts, degree symbols, mean symbols and Greek characters such as alpha, beta, gamma, etc. These symbols may or may not display properly on your desktop.
* The master procedures may also contain columns of tabbed data. Tab settings may or may not be displayed properly on your desktop.

3) The Adobe Acrobat PDF file provides a snapshot of the master procedure in a printable 8.5 x 11” format. It is provided to serve as a reference for accuracy.

4) By downloading this procedure, your institution is assuming responsibility for modification and usage.

**HELENA LABORATORIES**

**PROCEDURE DOWNLOAD END USER AGREEMENT**

HELENA LABORATORIES LABELING – Style/Format Outline

1. PRODUCT {Test} NAME
2. INTENDED USE and TEST TYPE (qualitative or qualitative)
3. SUMMARY AND EXPLANATION
4. PRINCIPLES OF THE PROCEDURE

{*NCCLS lists SAMPLE COLLECTION/HANDLING next}*

1. REAGENTS (name/concentration; warnings/precautions; preparation; storage; environment; Purification/treatment; indications of instability)
2. INSTRUMENTS required – Refer to Operator Manual (... for equipment for; use or function; Installation; Principles of operation; performance; Operating Instructions; Calibration\* {\*is next in order for NCCLS – also listed in “PROCEDURE”}’ precautions/limitations/hazards; Service and maintenance information
3. SAMPLE COLLECTION/HANDLING
4. PROCEDURE

{*NCCLS lists QUALITY CONTROL (QC) next}*

9) RESULTS (calculations, as applicable; etc.)

10) LIMITATIONS/NOTES/INTERFERENCES

11) EXPECTED VALUES

12) PERFORMANCE CHARACTERISTCS

13) BIBLIOGRAPHY (of pertinent references)

14) NAME AND PLACE OF BUSINESS OF MANUFACTURER

15) DATE OF ISSUANCE OF LABELING (instructions)

For Sales, Technical and Order Information, and Service Assistance,   
call Helena Laboratories toll free at 1-800-231-5663.

Form 364

Helena Laboratories

1/2006 (Rev 3)

**Cascade® Abrazo® c-ACT-LR Controls**

** 5727, 5728 **

**Contents**

**Cat. No. 5727 Level 1 - 10 x 1 mL vials**

**Cat. No. 5728 Level 2 - 10 x 1 mL vials**

# Intended Use

The Cascade Abrazo c-ACT-LR assayed controls are intended for use with the Cascade Abrazo analyzer and c-ACT-LR test cards to provide a method for quality control of the system. The assayed controls produce clotting times that must be within accepted, standard ranges to indicate that the analyzer and test cards are functioning accurately, and thereby ensure accuracy of the c-ACT-LR test card results. These controls can also be used to determine system (analyzer and c-ACT-LR test cards) precision.

Summary

Two levels of control plasma are recommended to ensure the accuracy of the c-ACT-LR test results. Level 1 provides a sample that will clot within the time range expected for a normal human sample. Level 2 mimics a sample from an individual receiving heparin in low to moderate (up to 3.0 U/mL) concentrations and will exhibit a prolonged clotting time.

Reagents

For *in vitro* diagnostic use only.

Level Volume Ingredients Storage Stability

1 1 mL Lyophilized preparation of human 2–8°C Unreconstituted – until the

plasma and an inert bulking agent. (36–46°F) expiration date on the vial label   
 Diluent prepared with deionized water,   
 NaCl, and an antimicrobial agent.

2 1 mL Lyophilized preparation of human 2–8°C Unreconstituted – until the  
 plasma and an inert bulking (36–46°F) expiration date on the vial label   
 agent. Diluent prepared with   
 deionized water, NaCl,an   
 antimicrobial agent, and an  
 antifoam reagent.

**CAUTION:** The reconstituted control is not stable. This preparation must be used within one minute after crushing the glass ampule, since the clotting reaction begins *immediately* upon mixing the diluent with the plasma. Clotting times increase with successive drops of the control suspension; therefore, use only one ampule per test card.

**POTENTIAL BIOHAZARD:** The controls are of human source material and should be treated as potentially infectious. Each donor unit used in the preparation of this product has been tested and found to be non-reactive for antibodies to HIV 1/2, HCV, and has tested negative for HBsAg. Because no known test method can offer complete assurance that infectious agents are absent, all human-based products should be handled in accordance with good laboratory practices, using appropriate precautions.1-4

**PRODUCT INTEGRITY:** Broken or cracked glass ampules in nonreconstituted vials of controls may cause erroneous results. Diluent should be clear and colorless.

**NOTE: Protective sleeve must be used to reconstitute and dispense the control material to avoid contact with biohazardous material.**

procedure

Materials provided: The following materials are contained in the Abrazo c-ACT-LR Control Kits.

**Cat. No.**

Cascade Abrazo c-ACT-LR Level 1 Control (10 vials) 5727

Cascade Abrazo c-ACT-LR Level 2 Control (10 vials) 5728

Materials provided but not contained in the kit:

**Item Cat. No.**

Cascade Abrazo Analyzer 5710

Cascade Abrazo Electronic QC (EQC) Test Card 5848

Cascade Abrazo c-ACT-LR Test Cards 5701

step-by-step

Equilibrate c-ACT-LR controls and test cards at room temperature (20 to 25°C, or 68 to 77°F) for 15 minutes before use. For c-ACT-LR test card instructions, refer to the c-ACT-LR package insert.

**WARNING: Do not reconstitute the control plasma until the test card has been warmed in the analyzer. Reconstituting the control plasma before warming the test card can cause erroneous results. The reconstituted control should be used immediately (within one minute).**

1. From the **MAIN MENU**, select **QC TEST** option.

2. Then select **LIQUID QC**. The unit will prompt the user to scan the test card barcode.

3. Place the test card in the analyzer and allow to warm.

4. The Abrazo prompts the user for the plasma control barcode.

5. Reconstitute the control plasma as follows:

a. Remove the shrink wrap from the plasma control.

b. Place the control vial in the protective sleeve.

c. Hold the vial in the protective sleeve and firmly bend the vial over the edge of a table top one or two times until the inner glass ampule is completely crushed.

d. Remove the vial from the sleeve and shake it vigorously 20 times or until no clumps of lyophilized plasma are visible. **WARNING:** Not following manufacturer’s reconstitution procedures may lead to skin punctures and exposure to biohazards.

e. Remove the colored cap exposing the dropper tip.

f. Replace the vial in the protective sleeve prior to dispensing the control material.

6. Immediately dispense **five (5) waste drops** of reconstituted control into a container approved for biohazardous material to clear the vial filter.

7. Holding the control vial at least one inch above the sample well on the test card, add one free falling drop of control. NOTE: Do not allow the control vial nor the hanging control drop to contact the test card when applying the control.

8. Sample placement automatically initiates testing. Results should be within the assay ranges given for each lot of control.

9. Dispose of the control vial and the test card in a manner approved for biohazardous material.

Quality Control

Daily quality control (QC) is a good laboratory practice and is required by most states in the U.S. and the Clinical Laboratory Improvement Amendment,1988 (CLIA ’88). Quality control procedures are part of an overall quality assurance program to ensure the accuracy and reliability of patient results and reports. Monitoring the results of QC analyses can alert you to possible system performance problems. Healthcare professionals should follow proper local and national guidelines for quality control and check with appropriate licensing/accrediting bodies to ensure the QC programs meet established standards.5

There are two types of quality control available for use on the Cascade Abrazo: Electronic Quality Control (EQC Test Card) and plasma controls.

The EQC Test Card ensures that the electronic components of the Cascade Abrazo analyzer are working properly. The purpose of the EQC Test Card is to offer a simple and economic alternative to the daily use of Cascade Abrazo test cards and plasma controls. However the EQC test card is ***not*** intended to permanently replace plasma controls. EQC quality control must be performed every 8 hours of operation when patient samples are tested.

It is imperative that, at a minimum, Level 1 and 2 plasma controls are tested:

• With each new box of test cards or at least once per week

• With each new shipment of test cards

• With each new lot number of test cards or controls

• Whenever improper storage or handling of test cards is suspected

• Whenever patient results appear abnormally high or low

Each facility should verify the assay ranges for each level of control. When changing the lot number of cards or controls, the user should be able to obtain mean values within the manufacturer’s assay range.

**Interpretation of Quality Control Results:** If the results fail to fall within assayed ranges, verify that the sample type chosen was “CONTROL PLASMA” and repeat with a new control vial. If the results continue to fall outside the assayed range, do not report any patient test results before contacting a supervisor qualified to resolve the problem.

Limitations

Variations in technique and ambient temperature may alter performance characteristics. It is important to follow the STEP BY STEP instructions in this package insert. The assay ranges are only for c-ACT-LR controls with the c-ACT-LR test cards, and only when tested on the Cascade Abrazo analyzer within 1 minute of reconstitution.

Performance Characteristics

**PRECISION:** The precision studies were performed using three lots of Cascade Abrazo c-ACT-LR Level 1 and Level 2 controls and one lot of Cascade Abrazo c-ACT-LR cards. The studies were performed by multiple non-laboratorian operators (POC) at three sites across 6 Cascade Abrazo analyzers. Each operator performed 2 runs per day, 2 tests per run on each lot of Abrazo c-ACT-LR test controls over a period of 20 days.

**Within-run, between run, and between day Precision\***

**N = 80**



**Lot to Lot Precision\***

**N = 80**



**Operator to Operator Precision\***

**N = 80**



\*Precision studies were performed according to EP05-A2.6

# References

**Références/Literatur/Riferimenti/Referencias**

1. Centers for Disease Control. Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other bloodborne pathogens in healthcare settings. MMWR, 1988; 37: 377–82, 387–8.

2. Clinical and Laboratory Standards Institute. Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline. CLSI Document M29-A3: Vol. 25 No. 10, 2005.

3. Federal Occupational Safety and Health Administration. Bloodborne Pathogens Standard. 29 CFR 1910.1030.

4. Biosafety in Microbiological and Biomedical Laboratories, U.S. Department of Health and Human Services, Washington [HHS Publication No. (CDC) 93-8395] 1993.

5. Clinical and Laboratory Standards Institute. Point-of-Care In Vitro Diagnostic (IVD) Testing; Approved Guideline. , CLSI Document POCT4-A2, Vol. 26 No. 30, 2006.

6. Clinical and Laboratory and Standards Institute: Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. CLSI Document EP05-A2, 2004.

For Sales, Technical and Order Information and Service Assistance, call 800-231-5663 toll free.

Helena Laboratories warrants its products to meet our published specifications and to be free from defects in materials and workmanship. Helena’s liability under this contract or otherwise shall be limited to replacement or refund of any amount not to exceed the purchase price attributable to the goods as to which such claim is made. These alternatives shall be buyer’s exclusive remedies.

In no case will Helena Laboratories be liable for consequential damages even if Helena has been advised as to the possibility of such damages.

The foregoing warranties are in lieu of all warranties expressed or implied including, but not limited to, the implied warranties of merchantability and fitness for a particular purpose.

 Helena Laboratories

1530 Lindbergh Drive

Beaumont, TX 77707 USA



Form 399-036

5/22(4)